Activating alterations of the RET kinase are therapeutically actionable oncogenic drivers across a variety of cancers; in-frame RET rearrangements occur in subsets of non-small-cell lung and papillary ...
Giovanna Whitting received selpercatinib to treat her thyroid cancer as part of a clinical trial when she was 16 years old. Today, she is a healthy, happy college student. “Selpercatinib has shown a ...
Here, we describe the ability of LOXO-292 to overcome acquired RET kinase domain mutations preclinically and in two patients with RET-altered cancers, one with acquired gatekeeper mutation resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results